SYNOPSIS A number of mathematical models have been tested for their suitability in representing the dose response curve of a specific assay of the hormone human placental lactogen (HPL) In the design of this assay kit2, working concentrations of antisetum and labelled HPL were set at much higher levels than would normally be encountered in the radioimmunoassay of many hormones. This allowed the direct assay of the relatively high concentrations of HPL encountered in the second half of pregnancy (Chard, 1973) . Greater precision in the range 3-6 ,ug HPL/ml was achieved by maximizing the slope of the dose response line in this region. A consequence of this design is that the slope of the curve in the 0-1 ,Iug HPL/ml region approaches zero as the antibody is almost unsaturated here. A restriction is set by the number of standard points available. Serum standards at four concentrations are supplied by the manufacturer. These 'The hormone human placental lactogen (HPL) is also known as human chorionic somatomammotrophin (HCS). 2The HPL immunoassay kit produced by the Radiochemical Centre, Amersham, England.
activity or counts bound to the antibody and X is the HPL concentration is proposed as representing the overall shape of the curve. This model is shown to give both an accurate representation of the curve and to allow reproducible determination of an unknown over a number of occasions. A number of other models are compared. The new model allows automatic calculation of HPL concentrations from a standard curve using a computer.
One important current development in the routine implementation of radioimmunoassay in clinical chemistry is the use of automatic data processing. Modern large computers reduce the amount of manpower required in calculation and can give more objective, reliable, and rapid results than manual methods. The use of numerical calculation depends on some kind of model which represents the doseresponse curve of the assay under consideration. This paper considers various possible models to represent the dose-response curve for one specific assay of HPL. An example of the curve is shown in the figure.
In the design of this assay kit2, working concentrations of antisetum and labelled HPL were set at much higher levels than would normally be encountered in the radioimmunoassay of many hormones. This allowed the direct assay of the relatively high concentrations of HPL encountered in the second half of pregnancy (Chard, 1973 (Rodbard and Lewald, 1970; Taljedal and Wold, 1970; Healy, 1972) . This curve gives a good fit in many assays but has not been found suitable to represent the HPL assay curve in this case where the slope approaches zero at zero HPL concentration.
There are a limited number of suitable functions which may possibly be used to represent a full immunoassay curve as shown in the figure. One suitable function has been suggested by Burger, Lea, and Rennie (1973 To decide the best model a comparison of the curves over a number of data sets was carried out as has already been done, for example, for an insulin assay (Meinert and McHugh, 1968 In the 0-2 ,ug HPL region the precision of the assay is low and this area is relatively unimportant; it is worth noting that the Amersham curves give the best representation in this region. However, any of the curves except the Burger fit would be acceptable as giving a fit of suitable precision. Indeed, the excellence of the manual fit, where all the curves were drawn by one experienced operator, is remarkable. 
Computing Consideration
The Amersham-3 and -4 curves are both highly nonlinear in their parameters. Sophisticated programs have been prepared for fitting both curves using ICL Fortran and subroutines from the Harwell library (Hopper, 1971) . A simplified program for the Amersham-3 curve has been prepared in Basic using the techniques presented by Burger et al (1973) . No problems of convergence have been seen in about 100 sets of data using the Basic program.
Conclusion
The Amersham-3 curve has been shown to give accurate and reproducible answers for a specific assay of HPL. It has been designed for this assay and cannot be used for other assays in the form presented. The general curve shape may prove extremely useful in representing other assay curves and it is proposed to proceed to investigate this possibility.
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The advantage of the Amersham curve type is that it may give a more accurate representation of the curve near zero dose and allow a more precise determination of assay sensitivity.
